BH-P-GLORA-4

A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).

Status:

OPEN TO ACCRUAL

Trial Type:
Age Group:
Adults
Phase:

III

NCT Number:
Contact:

Reagan, John